Rate of abnormal renal function index and related risk factors in patients with chronic hepatitis B

Table 2 Characteristics of β2 microglobulin normal and abnormal groups in treatment-experienced patients with any nucleos(t)ide

Patient characteristics	Normal β2-MG (n = 121)	Abnormal β2-MG (n = 165)	P value
Age (years)	43.63 ± 10.88	43.36 ± 10.63	0.83
Male, %	65.3	80	< 0.05
Family history, %	52.1	57.0	0.53
Hypertension, %	5.8	5.5	0.90
Diabetes, %	5.0	3.0	0.40
Fatty liver, %	22.3	25.5	0.64
Fibrosis, %	30.6	30.9	1.00
Cirrhosis, %	18.2	19.4	0.92
HCC, %	1.7	1.8	0.92
HBV DNA-positive, %	15.8	14.6	0.91
ALT, U/L	25.74 ± 22.26	31.6 ± 23.62	< 0.05
AST, U/L	23.33 ± 9.86	25.75 ± 18.12	0.18
Total bilirubin, μmol/L	13.38 ± 5.72	15.59 ± 10.26	< 0.05
Direct bilirubin, μmol/L	5.08 ± 1.90	5.86 ± 4.16	0.06
Blood urea nitrogen, mmol/L	4.74 ± 1.05	4.94 ± 1.20	0.14
eGFR, mL/min	96.06 ± 16.38	92.66 ± 15.70	0.08
Cholesterol, mmol/L	4.30 ± 0.91	4.28 ± 0.91	0.87
Triglyceride, mmol/L	1.16 ± 0.71	1.31 ± 1.13	0.18
High-density lipoprotein, mmol/L	1.33 ± 0.35	1.25 ± 0.32	< 0.05
Low-density lipoprotein, mmol/L	2.75 ± 0.80	2.70 ± 0.80	0.64
Duration of NUC treatment (years)	4.25 ± 3.53	4.30 ± 3.28	0.90

ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; β2-MG: β2 microglobulin; eGFR: Estimated glomerular filtration rate; HBV: Hepatitis B virus; HCC: Hepatocellular carcinoma; NUCs: nucleos(t)ide analog agents.